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ABSTRACT
Background: Evidence from recent years suggests most cases of hemoptysis to be caused by
non-malignant etiologies, but the long-term outcome for these patients has been less thoroughly
investigated. Objective: We aimed to assess the rates of hemoptysis recurrence, new lung cancer
diagnoses and death within 5 years of initial referral for hemoptysis. Design: In this retrospective
study, we reviewed clinical records of consecutive patients referred to evaluation for hemoptysis
with no malignancy suspected on chest computed tomography at Aalborg University Hospital,
Denmark, in a seven-year period from 2006 to 2012.
Results: A total of 609 patients (mean age 56.7 ± 14.1 years, 60.6% male) were included in the
study. The etiology was cryptogenic in 81% of patients and no patients had malignant disease. In
the following 5 years, lung cancer developed in 1.5% of patients. Median time to diagnosis was
26 (IQR 18–33) months. Nine percent of patients had at least one recurrence of hemoptysis, and
the 5-year mortality rate was 12% with median time to death 31 (IQR 13–43) months.
Conclusions: Lung cancer developed in less than 2% within 5 years after referral for hemoptysis
with no malignancy suspected on chest computed tomography. Further research is needed to
identify risk factors for the development of lung cancer in these patients.
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Introduction
Hemoptysis is defined as coughing up or spitting of blood
originating from the lower airways [1]. Although often
associated with serious disease by the patient and, to
some extent, health care professionals, evidence from
later years points to low proportions of lung cancer and
other serious conditions as etiologies of hemoptysis,
while common respiratory tract infections and crypto-
genic hemoptysis are more frequent [2–6].
The long-term outcomes in hemoptysis patients have
been less frequently studied than the immediate etiologies.
Studies from recent years have found very low incidences
of lung cancer in the years after initial referral for hemop-
tysis [6–10], even though a 3-year incidence of 10% was
reported in one larger study [5]. Reported mortality rates
in hemoptysis patients range from 4% at 1 year [11] to
around 20% at 2–3 years after initial referral for hemopty-
sis [5,9,12], while reports on recurrence rates of hemoptysis
are difficult to compare but also vary considerably from
0.3% at 1 year to 16.3% at 3 years [5,7,8,11]. The long-term
prognosis of patients with hemoptysis is not well known
regarding diagnoses such as Chronic Obstructive
Pulmonary Disease (COPD), asthma and bronchiectasis.
Guidelines recommend evaluation with fiberoptic
bronchoscopy and chest computed tomography (CT) in
patients with hemoptysis, but no consensus exists regard-
ing the necessity of follow-up in these patients. Thismay be
explained by the scarcity of evidence when it comes to the
natural history of hemoptysis and the patient prognoses.
Hypothesis and aims
We hypothesize that patients with hemoptysis and no
malignancy suspected on chest CT do not have recur-
rent episodes of hemoptysis and do not develop lung
cancer within 5 years.
Thus, primary outcomes are the proportion of this
patient group experiencing recurrent hemoptysis and
the proportion diagnosed with lung cancer within
5 years of initial referral for hemoptysis.
Secondary outcomes are the etiologies in recurrent
hemoptysis and the rates of new diagnoses of COPD,
asthma, bronchiectasis and interstitial lung disease
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within 5 years of referral. Lastly, we will determine the
5-year mortality rate in this patient group.
Materials and methods
Setup and study population
The patients presented in this study comprise part of
the study population presented in another study from
our group [13]. Said report is currently in submission.
We retrospectively reviewed clinical records of
patients referred to evaluation for hemoptysis at the
Department of Respiratory Diseases, Aalborg University
Hospital, Denmark. Study subjects were identified by the
ICD-10 code for hemoptysis, DR042. Consecutive
patients referred in a 7-year period from 1 January 2006
to 31 December 2012 were eligible for inclusion to allow
for a full 5-year follow-up.
The following exclusion criteria were applied: <18 years
of age; previous evaluation for hemoptysis; cancellation of
the clinical evaluation for any reason; bleeding not origi-
nating from the lower airways as assessed on first visit; no
chest CT or chest CT older than two months at referral;
and CT suspicious of pulmonary malignancy.
Data collection and definitions
From the patients’ case records from the first visit upon
referral, the following data were collected: gender and
age at referral; present somatic diseases (diagnoses
applicable to the patient at initial referral); previous
somatic diseases (diagnoses no longer applicable to
the patient at initial referral); and smoking history
(never, ex-smoker [>6 months absence], smoker). If
not noted independently, present somatic diseases
were estimated from the medication listed in the case
record. Smoking history in smokers and ex-smokers
was quantified in pack years (≤30/>30) [14].
Results of the chest CT were obtained from the radi-
ological description. Any abnormality of the lungs,
including bronchiectasis but excluding emphysematic
shape of the thorax and normal anatomical variations,
was considered a positive finding. Bronchoscopy results
were recorded as assessed by the procedure description
from the investigating physician. Bronchoscopy was con-
sidered macroscopically positive if: the site of bleeding
was identified; a tumor or foreign body was identified; a
substantially vulnerable mucosa was described; or seque-
lae after previous surgery were described.
Results of histological, cytological and microbiological
samples were obtained from the respective integrated
applications of the patients’ case records. Histology and
cytology were considered positive if suggestive of
dysplasia or malignancy. Metaplasia and inflammation
were not considered positive, unless the pattern of
inflammation suggested interstitial lung disease. As to
microbiology, any growth not described as normal flora
was considered positive, as was positive polymerase chain
reaction (PCR) for mycobacteria.
Etiologies of hemoptysis were defined as the diagnoses
stated or acted upon by the physician at the end of initial
diagnostic workup. Etiologies were grouped into primary
lung cancers, metastatic cancer to the lungs, mycobacter-
ial infections, fungal infections, other respiratory tract
infection (excluding mycobacterial and fungal infections)
and interstitial lung disease. All other etiologies were
recorded individually. In patients with more than one
diagnosis, all were recorded as etiologies. Cases with no
established etiology were recorded as cryptogenic.
Follow-up data were collected from clinical records
dated from a 5-year period after the initial referral for
hemoptysis and included: number of new episodes of
hemoptysis, and, for the first of these, etiology and
time from initial referral; new diagnoses of lung cancer,
COPD, asthma, bronchiectasis or interstitial lung dis-
ease and time from initial referral; death and time from
initial referral. Recurrent hemoptysis was recorded for
all new contacts with the ICD-10 diagnosis of hemop-
tysis that were not directly connected to the initial
referral for hemoptysis.
Data management, statistics and approvals
Study data were collected and managed using REDCap
electronic data capture tools hosted at Aalborg University
Hospital [15].
Descriptive statistics were carried out using the inte-
grated ‘Data Exports, Reports, and Stats’ module of
REDCap and IBM SPSS Statistics for Macintosh,
Version 25.0, the latter of which was also used for
hypothesis testing and multivariable regression.
Normally distributed data were presented as mean
and standard deviation (SD), while data with non-nor-
mal distribution were presented as median and inter-
quartile range (IQR). Frequencies were presented as
absolute numbers and percentages of cases with rele-
vant data available. Cox proportional hazards regres-
sion was applied to identify independent risk factors
during follow-up. Hazard ratios were presented along
with confidence intervals and p-values. A significance
level of 95% applied to all tests.
The study was approved by the Danish Patient Safety
Authority with case ID 3-3013-2350/1/and by the Danish
Data Protection Agency under the umbrella application
for the North Denmark Region (2008-58-0028) with pro-
ject ID 2017-60.
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Results
Study population and baseline characteristics
A total of 802 patients were referred to our clinic with
hemoptysis during the study period from 1 January
2006 to 31 December 2012. Of these, 193 met one or
more exclusion criteria, leaving 609 patients to be
included in the study. The inclusion process is depicted
in Figure 1.
The majority of patients were male, mean age was
56.7 years and 76.7% were current or previous smo-
kers. Baseline characteristics are shown in Table 1.
At initial referral, no present somatic disease was
known in 42.9% of patients. COPD was known in
13.5% of patients, 8.3% had asthma, and 1.3% already
had a diagnosis of bronchiectasis.
A previous history of lung cancer was known in
2.5% and of non-pulmonary cancer in 7.4%. Present
and previous health data are presented in Figure 2.
Results of initial diagnostic workup
All 609 patients had computed tomography performed,
and 28.7% had a radiological finding of bronchiectasis. In
total, 70.3% of CT scans were positive. Bronchoscopy was
performed in 92.8% of patients and macroscopically
Figure 1. Inclusion process and excluded patients by exclusion
criterium.
Table 1. Baseline characteristics in absolute numbers and per-
centages of patients with relevant data available, where not
stated otherwise.
Mean age (SD) (n = 609) 56.7 (14.1)
Male (n = 609) 369 (60.6)
Smoking (n = 600) 460 (76.7)
Current (n = 600) 258 (43.0)
Previous (n = 600) 202 (33.7)
Pack years >30 (n = 577) 155 (26.9)
Anticoagulant treatment (n = 592) 162 (27.4)
Amount of hemoptysis (n = 394)
Mild 340 (86.3)
Moderate–severe 49 (12.4)
Massive 5 (1.3)
Episodes (n = 546)
1 108 (19.8)
2–5 191 (35.0)
>5 247 (45.2)
Current/prev. lung disease (n = 601) 153 (25.5)
Figure 2. Patients with somatic disease diagnoses applicable at referral (present) and no longer applicable at referral (previous), as
percentage of patients with relevant data available (n).
EUROPEAN CLINICAL RESPIRATORY JOURNAL 3
positive in 38.7%. Microbiological sampling was per-
formed in 64.5% of patients, and 24.9% of these were
positive. Cytological evaluation was done in 58.4% of
patients with 1.4% of these turning out positive, while
histological evaluation of 7.4% of patients was positive in
7% of evaluated cases.
Cryptogenic hemoptysis was concluded in 80.5%
patients. No patients were diagnosed with primary or
metastatic cancer to the lungs. The most frequent etiol-
ogy was respiratory tract infection (13.6%) followed by
bronchiectasis (3.8%). Five patients had a double diag-
nosis of bronchiectasis and respiratory tract infection.
All etiologies are shown in Figure 3.
Five-year follow-up
In the follow-up period, 53 (8.7%) patients had at least
one recurrence of hemoptysis. Median time to first
recurrence was 15 (IQR 9–32) months. Of these, 89%
had only one recurrence. Most frequent etiologies at
first recurrence were cryptogenic hemoptysis (71%)
and infection (15%), while two patients (4%) were
diagnosed with lung cancer. Radiological findings of
bronchiectasis were not found to be an independent
risk factor for recurrence, and neither was age, gender,
current or previous lung disease or smoking history.
A total of nine (1.5%) patients, including the two men-
tioned above with recurrent hemoptysis, were diagnosed
with lung cancer (three small-cell carcinomas, three
adenocarcinomas, two non-specified non-small-cell
carcinomas and one unknown subtype). Median time to
diagnosis was 26 (IQR 18–33) months. Earliest diagnosis
was at 5 months and latest diagnosis at 52 months after
initial referral. One patient was 40 years old at initial
referral and the remaining eight patients 66–78 years old.
Six were female, and eight were current or previous smo-
kers, while smoking history was unknown in one patient.
Two patients were previously treated for lung cancer and
one was previously treated for a non-pulmonary cancer.
One had COPD. At initial diagnostic workup, three had a
normal CT, and seven underwent bronchoscopy, four of
which were macroscopically positive. Histological evalua-
tion was performed in one patient and cytologic evaluation
in four patients. All turned out negative. Eight had crypto-
genic hemoptysis, while one had a respiratory tract infec-
tion. All nine patients died during follow-up.
In total, 5.3% of patients had a new diagnosis of
chronic lung disease during follow-up. All new diag-
noses are presented in Table 2.
The 5-year mortality rate was 12%. Median time
from initial referral to death was 31 (IQR 13–43)
months. From Cox proportional hazards regression,
independent risk factors for death during follow-up
were increasing age (HR 1.07, CI 1.05–1.10,
p < 0.001), current or previous lung disease (HR 1.97,
CI 1.18–3.30, p = 0.01), previous lung cancer (HR 3.44,
CI 1.46–8.10, p = 0.005) and current or previous smok-
ing history (HR 2.26, CI 1.08–4.76, p = 0.031). Gender
was not found to be an independent risk factor
(p = 0.296).
490 (80.5%)
83 (13.6%)
23 (3.8%)
5 (0.8%)
3 (0.5%)
2 (0.3 %)
2 (0.3 %)
1 (0.2%)
1 (0.2%)
1 (0.2%)
1 (0.2 %)
1 (0.2 %)
1 (0.2 %)
0 (0 %)
0 100 200 300 400 500
Cryptogenic
Bronchiectasis
Interstitial lung disease
Asthma
Pulmonaryembolism
Fungal infection
COPD
Hemangioma
Wegener'sgranulomatosis
Mycobacteria
Leiomyoma
Intrathoracic goiter
Malignancy
Respiratory tract infection
Figure 3. Patients according to etiology established at initial diagnostic workup.
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Discussion
In this study, we found a recurrence rate in hemoptysis of
8.7% in 5 years, which is comparable to the study by
Delage et al., who found a recurrence rate of 8% at a
mean follow-up of 5 years [7], while others found higher
recurrence rates ranging from 11% to 20% at approxi-
mately 1 year’s follow-up [5,8,11]. We did not identify
any independent risk factors for recurrence. Notably,
radiological findings of bronchiectasis were not signifi-
cantly associated with recurrence. This has not been
investigated in previous reports. Most cases comprised
benign causes, but 4% of first recurrences were caused by
lung cancer, indicating that patients with recurrence
should be investigated thoroughly as the risk of cancer
is higher than for incidence cases of hemoptysis.
The rate of lung cancer diagnosed in the 5 years fol-
lowing initial referral was 1.5%. This is comparable to
results from previous studies, although these all have
shorter follow-up periods than our study. Thirumaran
et al. reported 0.4% of hemoptysis patients with normal
chest x-ray to develop lung cancer during a mean follow-
up of three years [6], while Tsoumakidou et al. found no
new lung cancers in 189 hemoptysis patients during an
average follow-up of 2.7 years [9]. Bønløkke et al. found
no lung cancers within two years of initial referral for
hemoptysis in a group of 78 patients with no pathology
on CT [2]. A larger French study evaluated the three-year
outcomes of around 30,000 hemoptysis patients and esti-
mated 4% of patients with cryptogenic hemoptysis to be
diagnosed with lung cancer during follow-up [5].
All but one patient diagnosed with cancer in our
follow-up were verified smokers, while one did not
have data available on smoking. Eight out of nine
were substantially older than the average patient in
our population. Correspondingly, Herth et al., who
reported a lung cancer rate of 6% at a mean follow-
up of 6.6 years, found all cancers during follow-up to
occur in smokers over 40 years [10]. Also comparable
to our findings, these cases were diagnosed before
3 years. With the earliest cancer diagnosis in our
study established at 5 months and median time to
diagnosis 26 months, the question could be raised if
these represent missed cases of cancer at initial
diagnostic workup. However, the histologic and cyto-
logic evaluations performed in these patients were all
negative.
In our study, one third of patients with a new cancer
diagnosis were previously treated for cancer, two of
which were lung cancers, indicating that these patients
may comprise a group of particular interest with regard
to follow-up after incident cases of hemoptysis.
Statistical assessment in the form of Cox proportional
hazards regression to identify individual risk factors
would be beneficial, but due to the low number of
cancer cases, this was not deemed meaningful [16].
The low rate of new diagnoses during follow-up (5%)
indicates that the initial workup is effective in diagnosing
chronic lung conditions. This has not previously been
investigated systematically and may reflect the fact that
a large proportion of patients already have chronic lung
diseases before the incident case of hemoptysis.
Seven patients had a new diagnosis of bronchiectasis
within 5 years, although bronchiectasis was identified
radiologically in 123 patients at initial diagnostic
workup but only recorded as the etiology of hemopty-
sis in 23 patients. Thus, the apparent underreporting of
bronchiectasis as the etiology may either question the
clinical significance of these radiological findings or
indicate a lack of awareness of the diagnosis.
The mortality rate of 12% at 5 years is low compared
to similar studies. Reports from Greece and Turkey
found markedly higher mortality rates although their
follow-up period was shorter [9,12]. This may in part
be explained by the high frequencies of lung cancer at
initial workup compared to our study. Interestingly,
the French study reported three-year mortality rates
of around 20% when excluding deaths from lung can-
cer [5], representing a rather large, unexplained differ-
ence to our study. More similar to our findings, Herth
et al. reported 13% of patients with cryptogenic
hemoptysis to be dead at 6.6 years [10].
The independent risk factors for death identified in
this study (increasing age, current or previous lung
disease, current or previous smoking history and pre-
vious lung cancer) have not been systematically
assessed in previous studies, which may explain the
differences in results.
This study is among the largest studies regarding
long-term outcome of hemoptysis. This allowed statis-
tical analysis of infrequent variables and outcomes,
although some outcomes were too rare to yield mean-
ingful statistical assessment. The large number of
patients with cryptogenic hemoptysis, in whom one
might suspect overlooked etiologies, enabled us to
show that even in these patients, severe disease is rarely
seen in the years following hemoptysis.
Table 2. Diagnoses during follow-up and median time to
diagnosis.
Diagnosis within
5 years
Patients
diagnosed (%)
Median time to diagnosis,
months (IQR)
Cancer 9 (1.5) 26 (18–33)
COPD 6 (1) 38 (11–47)
Bronchiectasis 7 (1.1) 9 (5–54)
Asthma 5 (0.8) 22 (11–23)
Interstitial lung
disease
5 (0.8) 18 (10–21)
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The retrospective design has several built-in limita-
tions, not least missing data and the need to interpret
clinical records. This also limited the assessment of
some variables, e.g. the quantification of pack-years as
≤/>30 which is an arbitrary limit. With regard to selec-
tion bias, some patients were excluded because they
declined evaluation, which may be due to very poor
health and thereby comprises a possible bias of our
results. However, the proportion of patients excluded
was small and we do not believe this to influence our
results significantly.
Conclusion
Recurrence of hemoptysis was seen in 8.7% within
5 years and 4% of these were caused by lung cancer.
Only 1.5% of hemoptysis patients with no malignancy
suspected on CT developed lung cancer within 5 years
of initial referral. Although the number of cancer cases
in our study was limited, our data indicate smokers and
patients previously treated for cancer to be of particular
interest with regard to establishing follow-up programs
for hemoptysis patients.
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